Recro Pharma Inc (REPH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Recro Pharma Inc (REPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9931
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Recro Pharma Inc (Recro Pharma) is a specialty pharmaceutical company that focuses on developing novel products for commercialization in hospital and other acute care settings and provides contract development and manufacturing (CDMO) services. The company is developing IV/IM Meloxicam, a proprietary, rapid-onset, long-acting preferential COX-2 inhibitor for the treatment of acute post-operative pain and acute pain; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine for the treatment of peri-procedural pain and cancer breakthrough pain. It also develops and manufactures pharmaceutical products based on its proprietary delivery technologies for commercial partners. Recro Pharma is headquartered in Malvern, Pennsylvania, the US.

Recro Pharma Inc (REPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recro Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Recro Pharma Acquires Certain Assets from Alkermes 10
Licensing Agreements 12
Recro Pharma Enters into Licensing Agreement with Cornell University 12
Pernix Therapeutics Enters into Licensing Agreement with Recro Pharma 13
Equity Offering 14
Recro Pharma Plans to Raise up to USD40 Million in Public Offering of Shares 14
Recro Pharma Plans to Raise USD20 Million in Public Offering of Shares 15
Recro Pharma Raises USD40 Million in Public Offering of Shares 16
Recro Pharma Raises USD7.8 Million in Private Placement of Shares 18
Recro Pharma Raises USD15 Million in Public Offering of Shares 19
Recro Pharma Raises USD16 Million in Private Placement of Shares 21
Recro Pharma Completes IPO For US$34.5 Million 22
Recro Pharma Inc – Key Competitors 23
Recro Pharma Inc – Key Employees 24
Recro Pharma Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2018: Recro Pharma Reports third quarter 2018 financial results raising guidance for CDMO business for 2018 26
Aug 07, 2018: Recro Pharma announces second quarter 2018 financial results 28
May 09, 2018: Recro Pharma Reports First Quarter 2018 Financial Results 30
Feb 27, 2018: Recro Pharma Announces Year End 2017 Financial Results 32
Nov 09, 2017: Recro Pharma Reports Third Quarter 2017 Financial Results 34
Aug 10, 2017: Recro Pharma Reports Second Quarter 2017 Financial Results 36
May 11, 2017: Recro Pharma Reports First Quarter 2017 Financial Results 38
Mar 06, 2017: Recro Pharma Reports Year End 2016 Financial Results 40
Corporate Communications 42
Jun 06, 2017: Recro Pharma Appoints Ryan D. Lake as Senior Vice President of Finance and Chief Accounting Officer 42
Mar 06, 2017: Recro Pharma appoints new board member 43
Clinical Trials 44
Apr 30, 2018: Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Recro Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recro Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recro Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recro Pharma Acquires Certain Assets from Alkermes 10
Recro Pharma Enters into Licensing Agreement with Cornell University 12
Pernix Therapeutics Enters into Licensing Agreement with Recro Pharma 13
Recro Pharma Plans to Raise up to USD40 Million in Public Offering of Shares 14
Recro Pharma Plans to Raise USD20 Million in Public Offering of Shares 15
Recro Pharma Raises USD40 Million in Public Offering of Shares 16
Recro Pharma Raises USD7.8 Million in Private Placement of Shares 18
Recro Pharma Raises USD15 Million in Public Offering of Shares 19
Recro Pharma Raises USD16 Million in Private Placement of Shares 21
Recro Pharma Completes IPO For US$34.5 Million 22
Recro Pharma Inc, Key Competitors 23
Recro Pharma Inc, Key Employees 24
Recro Pharma Inc, Subsidiaries 25

List of Figures
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Recro Pharma Inc (REPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Berkshire Hathaway Inc:企業の戦略・SWOT・財務分析
    Berkshire Hathaway Inc - Strategy, SWOT and Corporate Finance Report Summary Berkshire Hathaway Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Intersurgical Ltd.:企業の戦略的SWOT分析
    Intersurgical Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • New Carolin Gold Corp:企業の戦略・SWOT・財務情報
    New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report Summary New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Chrono Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Chrono Therapeutics Inc (CTI) is a personalized medicine manufacturer that provides programmable passive transdermal drug delivery products. The company provides smartstop, a programmable smoking cessation therapy that helps people to quit smoking and improve cessation outcomes. Its wearable …
  • Noble Energy, Inc.:企業の戦略・SWOT・財務分析
    Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • BioTime Inc (BTX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also develo …
  • Genextra Spa-製薬・医療分野:企業M&A・提携分析
    Summary Genextra SpA (Genextra) is a pharmaceutical company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, mono therapy and diabetes, INT- 777 for metabolic syndrome; novel HDAC and HSP90 inhibitors for the treatment of cancer; mj …
  • Dynavax Technologies Corp (DVAX):企業の財務・戦略的SWOT分析
    Dynavax Technologies Corp (DVAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • London North West Healthcare NHS Trust:企業の戦略的SWOT分析
    London North West Healthcare NHS Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Neurim Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Neurim Pharmaceuticals Ltd (Neurim) is a drug discovery company that develops drugs for central nervous system diseases.The company's product line includes circadin that is used in insomnia treatment. Neurim offers paediatric prolonged-release melatonin, piromelatine, NEU-P12 and NEU-240. Th …
  • Auris Medical Holding AG (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding AG (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Thai Beverage Public Company Limited:戦略・SWOT・企業財務分析
    Thai Beverage Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Thai Beverage Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • 88 Energy Ltd (88E):企業の財務・戦略的SWOT分析
    Summary 88 Energy Ltd (88 Energy), formerly Tangiers Petroleum Ltd, is an exploration and production company that develops oil-rich provinces. The company offers discovery, exploration and development of onshore oil projects. It has oil and gas assets in Morocco and Australia. 88 Energy’s Morocco pr …
  • Lee Enterprises, Inc. (LEE):企業の財務・戦略的SWOT分析
    Lee Enterprises, Inc. (LEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Aer Lingus Ltd:企業の戦略・SWOT・財務情報
    Aer Lingus Ltd - Strategy, SWOT and Corporate Finance Report Summary Aer Lingus Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • ASUSTeK Computer Inc.:企業の戦略・SWOT・財務情報
    ASUSTeK Computer Inc. - Strategy, SWOT and Corporate Finance Report Summary ASUSTeK Computer Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Entergy New Orleans Inc:電力:M&Aディール及び事業提携情報
    Summary Entergy New Orleans Inc (Entergy) a subsidiary of Entergy Corporation is an electric utility company that offers power distribution services. The company provides electric distribution, account management, payment options and services, community services, business and economic development. I …
  • AF Gruppen ASA (AFG):企業の財務・戦略的SWOT分析
    AF Gruppen ASA (AFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Briggs & Stratton Corp (BGG):企業の財務・戦略的SWOT分析
    Briggs & Stratton Corp (BGG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Geron Corp (GERN):製薬・医療:M&Aディール及び事業提携情報
    Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆